DE69721120D1 - Verwendung von menschlichen Chemokin beta-9 zur Behandlung von Atemnotsyndrom bei Erwachsenen - Google Patents

Verwendung von menschlichen Chemokin beta-9 zur Behandlung von Atemnotsyndrom bei Erwachsenen

Info

Publication number
DE69721120D1
DE69721120D1 DE69721120T DE69721120T DE69721120D1 DE 69721120 D1 DE69721120 D1 DE 69721120D1 DE 69721120 T DE69721120 T DE 69721120T DE 69721120 T DE69721120 T DE 69721120T DE 69721120 D1 DE69721120 D1 DE 69721120D1
Authority
DE
Germany
Prior art keywords
adults
treatment
respiratory distress
distress syndrome
human chemokine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69721120T
Other languages
English (en)
Other versions
DE69721120T2 (de
Inventor
John Richard White
Louis Martin Pelus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of DE69721120D1 publication Critical patent/DE69721120D1/de
Application granted granted Critical
Publication of DE69721120T2 publication Critical patent/DE69721120T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Cephalosporin Compounds (AREA)
DE69721120T 1996-05-14 1997-05-12 Verwendung von menschlichen Chemokin beta-9 zur Behandlung von Atemnotsyndrom bei Erwachsenen Expired - Fee Related DE69721120T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1787196P 1996-05-14 1996-05-14

Publications (2)

Publication Number Publication Date
DE69721120D1 true DE69721120D1 (de) 2003-05-28
DE69721120T2 DE69721120T2 (de) 2003-12-04

Family

ID=21785003

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69721120T Expired - Fee Related DE69721120T2 (de) 1996-05-14 1997-05-12 Verwendung von menschlichen Chemokin beta-9 zur Behandlung von Atemnotsyndrom bei Erwachsenen

Country Status (5)

Country Link
US (5) US6290948B1 (de)
EP (1) EP0807439B1 (de)
JP (2) JPH1053533A (de)
DE (1) DE69721120T2 (de)
DK (1) DK0807439T3 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6811773B1 (en) 1993-12-22 2004-11-02 Human Genome Sciences, Inc. Human monocyte colony inhibitory factor (M-CIF) polypeptides
US6451562B1 (en) 1993-12-22 2002-09-17 Human Genome Sciences, Inc. Polypeptides encoding myeloid progenitor inhibitory factor-1 (MPIF-1) polynucleotides
US6488925B2 (en) 1993-12-22 2002-12-03 Human Genome Sciences, Inc. Macrophage inflammatory protein-4 (MIP-4) polypeptides
US6495129B1 (en) 1994-03-08 2002-12-17 Human Genome Sciences, Inc. Methods of inhibiting hematopoietic stem cells using human myeloid progenitor inhibitory factor-1 (MPIF-1) (Ckbeta-8/MIP-3)
PL326080A1 (en) * 1995-09-29 1998-08-17 Smithkline Beecham Corp Short forms of chemokin beta-8
US6713052B1 (en) 1995-10-24 2004-03-30 Human Genome Sciences, Inc. Method of mobilizing stem cells with chemokine β-8
US6290948B1 (en) * 1996-05-14 2001-09-18 Smithkline Beecham Corporation Method of treating sepsis and ARDS using chamohine beta-10
US6632425B1 (en) 1997-03-20 2003-10-14 Human Genome Sciences, Inc. Chemokine compositions
US7067117B1 (en) 1997-09-11 2006-06-27 Cambridge University Technical Services, Ltd. Compounds and methods to inhibit or augment an inflammatory response
US6989435B2 (en) 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
KR19990042713A (ko) * 1997-11-27 1999-06-15 허일섭 사람에서 분리한 c 6 베타-케모카인 lkn-1의 cdna 및 재조합 lkn-1의 제조방법
AU1824499A (en) * 1997-12-30 1999-07-19 Chiron Corporation Human cxc chemokine ((tim-1))
US6495128B1 (en) 1998-11-10 2002-12-17 Human Genome Sciences, Inc. Human chemokine β-7 deletion and substitution proteins
US7238711B1 (en) 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
AU2002221099A1 (en) * 2000-12-08 2002-06-18 Takeda Chemical Industries Ltd. Combination drugs
EP1641484A2 (de) * 2003-05-09 2006-04-05 Schering Aktiengesellschaft Behandlung von entzündlichen atemwegserkrankungen
US8329169B2 (en) 2003-05-15 2012-12-11 Genentech, Inc. Methods and compositions for the prevention and treatment of sepsis
JP2008523083A (ja) * 2004-12-08 2008-07-03 イムノメディクス， インコーポレイテッド 炎症性疾患および免疫調節不全疾患、感染性疾患、病的血管新生およびがんの免疫療法および検出のための方法および組成物
ES2550389T3 (es) 2007-03-28 2015-11-06 Universidad De Barcelona Producto de CD6 para el tratamiento de enfermedades infecciosas y procesos inflamatorios relacionados
SG191716A1 (en) 2010-11-19 2013-08-30 Toshio Imai Neutralizing anti-ccl20 antibodies
EP3541407A1 (de) 2016-11-18 2019-09-25 Universitat de Barcelona Kombinierte cd6- und imipenem-therapie zur behandlung von infektionskrankheiten und damit verbundenen entzündungsprozessen

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897348A (en) * 1983-08-25 1990-01-30 Sri International Recombinant materials and methods for producing human connective tissue-activating peptide-III and analogs thereof
US4897338A (en) * 1987-08-03 1990-01-30 Allied-Signal Inc. Method for the manufacture of multilayer printed circuit boards
AU634508B2 (en) * 1988-12-08 1993-02-25 Sandoz Ag Neutrophil-activating peptide-2
US5212073A (en) * 1989-05-12 1993-05-18 Genetics Institute, Inc. Process for producing human JE cytokine
US5179078A (en) * 1989-05-12 1993-01-12 Dana Farber Cancer Institute Method of suppressing tumor formation in vivo
CA2064558C (en) * 1989-09-25 2001-01-30 Ian B. Pragnell Method for inhibiting growth of stem cells
NZ237202A (en) * 1990-02-23 1994-01-26 Bristol Myers Squibb Co Composition containing beta-lactam antibiotic and cationic oligopeptide
JPH06503710A (ja) * 1990-09-14 1994-04-28 カイロン　コーポレイション 酵母細胞におけるマクロファージ誘導タンパク質（ｍｉｐ）の発現
US5401651A (en) * 1991-10-16 1995-03-28 Walz; Alfred DNA encoding ENA-78, a neutrophil activating factor
US5306709A (en) * 1991-11-15 1994-04-26 The University Of Pennsylvania Suppression of megakaryocytopoiesis by macrophage inflammatory proteins
US5413778A (en) * 1992-10-05 1995-05-09 The Regents Of The University Of Michigan Labelled monocyte chemoattractant protein material and medical uses thereof
US5346686A (en) * 1992-10-05 1994-09-13 Mallinckrodt Medical, Inc. Labelled interleukin-8 and medical uses thereof
US5474983A (en) * 1993-03-15 1995-12-12 The Research Foundation Of State University Of New York Method of inhibiting pro-inflammatory mediator release from basophils and mast cells
US5346685A (en) * 1993-04-23 1994-09-13 Mobil Oil Corp. Synthetic porous crystalline MCM-51, its synthesis and use
JPH0789866A (ja) * 1993-09-21 1995-04-04 Nippon Kayaku Co Ltd 感染防御剤
CA2179606A1 (en) * 1993-12-22 1995-06-29 Haodong Li Macrophage inflammatory proteins-3, -4 and -1.gamma.
EP0770086A4 (de) * 1994-05-16 1998-07-15 Human Genome Sciences Inc Makrophagenmigration inhibierender faktor-3
PT799311E (pt) * 1994-08-23 2005-05-31 Human Genome Sciences Inc Quimiocina beta-9 humana
DE69433648T2 (de) * 1994-08-23 2005-02-17 Human Genome Sciences, Inc. Menschliche chemokin-polypeptide
WO1996009062A1 (en) * 1994-09-23 1996-03-28 University Of Nebraska Board Of Regents Polypeptide agonists and antagonists of human interleukin-8
US5602008A (en) * 1994-11-29 1997-02-11 Incyte Pharmaceuticals, Inc. DNA encoding a liver expressed chemokine
CN1190991A (zh) * 1995-06-05 1998-08-19 人类基因组科学公司 人类趋化因子β－11和人类趋化因子α－1
DE69533627T2 (de) * 1995-06-06 2005-10-13 Human Genome Sciences, Inc. Humanes chemokin beta-13
WO1996039520A1 (en) * 1995-06-06 1996-12-12 Human Genome Sciences, Inc. Human chemokine beta-12
EP0871664B1 (de) * 1995-10-24 2004-01-02 Smithkline Beecham Corporation Mobilisierung von haematopoietischen stammzellen durch ein chemokin
ZA968896B (en) * 1995-10-24 1997-04-24 Smithkline Beecham Corp Method of mobilizing hematopoietic stem cells
ZA969721B (en) * 1995-11-21 1997-11-28 Smithkline Beecham Corp Method of treating sepsis.
EP0885293B1 (de) * 1996-02-23 2006-06-07 Human Genome Sciences, Inc. Menschliche chemokin-polypeptide.
US6509313B1 (en) * 1996-02-28 2003-01-21 Cornell Research Foundation, Inc. Stimulation of immune response with low doses of cytokines
CA2249995A1 (en) 1996-03-18 1997-09-25 Human Genome Sciences, Inc. Chemokine alpha 3
CA2250576A1 (en) * 1996-03-27 1997-10-02 Icos Corporation Monocyte chemotactic protein-5 materials and methods
US6290948B1 (en) * 1996-05-14 2001-09-18 Smithkline Beecham Corporation Method of treating sepsis and ARDS using chamohine beta-10
GB9617923D0 (en) * 1996-08-28 1996-10-09 Smithkline Beecham Plc Novel receptor
WO1998011226A2 (en) * 1996-09-10 1998-03-19 Schering Corporation Mammalian chemokines, related reagents
WO1998014573A1 (en) * 1996-09-30 1998-04-09 The General Hospital Corporation Mcp-4 and mcp-5: novel chemokines

Also Published As

Publication number Publication date
US20020146390A1 (en) 2002-10-10
US20020141972A1 (en) 2002-10-03
US6406688B1 (en) 2002-06-18
EP0807439B1 (de) 2003-04-23
DK0807439T3 (da) 2003-08-11
US6290948B1 (en) 2001-09-18
DE69721120T2 (de) 2003-12-04
JPH1053533A (ja) 1998-02-24
US20020155094A1 (en) 2002-10-24
JP2001122801A (ja) 2001-05-08
EP0807439A3 (de) 1998-03-11
EP0807439A2 (de) 1997-11-19

Similar Documents

Publication Publication Date Title
DE69721120D1 (de) Verwendung von menschlichen Chemokin beta-9 zur Behandlung von Atemnotsyndrom bei Erwachsenen
DE69726245D1 (de) Befeuchtungsgerät zur Behandlung von Atemstillstand im Schlaf
DE69941566D1 (de) N-acetylhomotaurinate zur verwendung in der behandlung von hyperkinesie
ATE246500T1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen erkrankungen der atemwege
ATE349428T1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
DE69916686D1 (de) Gerät zur Behandlung von Atemstillstand im Schlaf
DE69600307D1 (de) Beatmungsgerät zur Behandlung von Ateminsuffizienzen
DE69830660D1 (de) Behandlung von atemstillstand im schlaf
DE69631157D1 (de) Pharmazeutische Zubereitung zur Verwendung in der Behandlung von Diabetes
DE69823459D1 (de) Herzbehandlungssystem zur Feststellung und Behandlung von Herzversagen
DE69202207D1 (de) Verfahren zur Herstellung von 1-Chlor-1,1,3,3,3-Pentafluorpropan und von 1,1,1,3,3,3-Hexafluorpropan.
DE69739303D1 (de) Vorrichtung zur thermischen behandlung von gewebe
ATE214274T1 (de) Antikonvulsiva zur verwendung bei der behandlung von amyotropischer lateralsklerose
TR199901772T2 (de)
DE68910175D1 (de) Adsorbermodul sowie Adsorberapparat zur Behandlung von Vollblut.
DE59206237D1 (de) Strahlmittel, Verfahren zur Herstellung desselben sowie Verwendung des Strahlmittels
DE69824576D1 (de) Verwendung von tetrahydropyridinderivaten zur herstellung von arzneimitteln zur behandlung demyelinisierender erkrankungen
DE69216615D1 (de) Entwässerte Blutzellen und Verfahren zur Herstellung
DE69734296D1 (de) Neue dikaffeoylchinasäurederivate und deren verwendung zur behandlung von hepatitis b
ATE347372T1 (de) Vakzine zur behandlung von mycosen
DE69531132D1 (de) Blattförmiger Sauerstoff-Absorber und Verfahren zur Herstellung
DE69633985D1 (de) Behandlung von Chromoxid und dessen Verwendung in der katalytischen Herstellung von Vinylfluorid
DE69434777D1 (de) Verwendung von Relaxin zur Herstellung von therapeutischen Mitteln
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
ATE77560T1 (de) Verwendung von 2-oxo-pyrrolidin-1-acetamid zur bestimmung der glomerulaeren filtrationsrate beim menschen.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee